and Lorry, this conference afternoon's Thank welcome call. you, to
are Joining Financial David Officer; today and Officer. Chief Operating Kirske, me Chief Bruce Seeley,
questions. the be remarks, call for formal Following conference open will
from to, this I Private Reform call, statements Before Securities section. Such statements views with the of on as Such XXXX not of may Litigation the the our forward looking uncertainties expectations. results beyond are the guarantees current of to note Report types date to forward-looking risks that of which provisions statements many of periodic not the and only our filed materially XXXX, are Act please that forward call anticipated and our subject are that fiscal control. future Safe including on cause actual based we be identified Harbor March are and SEC, making not and Investor XX-K statements, and begin, our statements Form will are including this those limited in on forward-looking XX, available represent Annual but that on within by reports as meaning the statements filed performance are differ during of website our of the looking in was the XXXX, subsequent
statements, results For filed please further looking description as to materially the with well differ to actual those our that risks from in see and cause of reports our forward as the risks would periodic expressed the SEC. uncertainties business, related
approval with the this pacritinib the The NDA's and to in review submission of area. continued advance for launch in unmet FDA's have myelofibrosis of towards year. priority pacritinib potential we patients this need underscores quarter, U.S. our a medical thrombocytopenia, This acceptance use with commercial
meeting XX, November is date an committee advisory not to FDA action is and XXXX, discuss target PDUFA the to currently planning the hold Our application.
and included than the Phase Patients focus data both studies counts and pre-commercialization XXX with severe of has patients access, chain, thirds deployments. with urgent is treatment trials patient and new clinical JAKX the To receiving XX population with those diligently the working options a on One Phase times the the limited including NDA with PERSIT-X PERSIST-X need accepted been and our were and patients the NDA frontline has population for existing X on based to that these myelofibrosis patients a X thrombocytopenic the treatment-naive activities, in pacritinib and reminder, distributions, a therapies. approximately patients, on per market thrombocytopenic, and team exposure focus prior PACXXX litre. field was and in severe platelet patients. day from this inhibitors. A As suboptimal X,XXX supply force thrombocytopenic address need, with education of disease less milligrams XX X to twice enrolled severely
have and our to sales pacritinib or the for we will completed the immediately of recruit launch leadership status, from the and we prepared on our review eager are started earlier. given our who PDUFA We commercially early managers an priority foreclosed FDA, application's launch date our to preparation key force. are In to hiring be account upon team launch, approval
by oxygenation of blind primary pacritinib study, extra standard comparing clinical PRE-VENT, Moving launched corporal end This will care in day points of year mechanical hospitalized the X severe proportion a care who XX. Phase patients in trial controlled and/or on to with versus study die COVID-XX. in or placebo of invasive plus pandemic. is of use standard assess The plus the membrane of trial progressed patients ventilation pacritinib the we a placebo response from myelofibrosis, of the double COVID-XX last to multicenter severe patients randomized
analysis interim to continue this report We expect outcome trial the to in the quarter. -- during from of this on
as low of host around in X/X tacrolimus pacritinib treatment of update prophylaxis to track ongoing an The And continues graft on to the or in progress have year. GVHD standard prevention the later addition any the enroll. investigator remain the GVHD. Finally, of study provide dose indication in and potential sirolimus to versus previously X investigating pacritinib acute the use Phase the component the regulatory of and investigating the disease we the Phase on of of interactions of trial discussed, are sponsored we we Phase X this
As the XXXX, regime, acute host pacritinib data in the in prophylaxis adding in meeting patients XXX transplantation to study to outcomes first expected safety and the I rates resulting without historical is review of showed standard significant from reminder, reduction versus quarterly American call December, a to that within David the Society presented compromising as Hematology this will new any compared now data days financials. to without turn the David? concerns. therapy our graft
